TexMex

@TraderTexMex

My tweets are NOT investment advice. My tweets are personal opinion only.

Vrijeme pridruživanja: svibanj 2009.

Tweetovi

Blokirali ste korisnika/cu @TraderTexMex

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @TraderTexMex

  1. prije 7 sati

    Zion Oil & Gas enters LOI to Purchase a Drilling Rig for Israel Operations

    Poništi
  2. prije 7 sati

    down 41% after failed Phase 3

    Poništi
  3. prije 7 sati

    RECOVERY Study has Stopped Enrollment Due to Inadequate Separation from Placebo at Week-12 Based on Interim Analysis Results of the First 50% of Enrolled Participants

    Poništi
  4. prije 7 sati

    Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD

    Poništi
  5. prije 7 sati

    halt

    Poništi
  6. prije 8 sati

    $50m ATM offering in S-3/a

    Poništi
  7. prije 8 sati

    8-k only 2m share offering at .80/share

    Poništi
  8. prije 8 sati

    6m share offering

    Poništi
  9. prije 12 sati

    1 for 10 reverse split, effective tomorrow

    Poništi
  10. prije 15 sati

    Cemtrex Develops VR Training Application for Cartier

    Poništi
  11. prije 16 sati

    27.8m shares price at $3.25/share

    Poništi
  12. prije 16 sati

    Genprex to Focus Its Clinical Efforts on Oncoprex™ in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC)

    Poništi
  13. prije 16 sati

    Maxim initiated Buy with $.50/share PT

    Poništi
  14. prije 16 sati

    We said Monday morning they needed cash, Nestle is their "sugar" daddy. Still a great win on short side $38-39 to sub $30. And now they've got their cash for the launch.

    Poništi
  15. prije 17 sati

    Nestle now owns 25.6% stake

    Poništi
  16. prije 17 sati

    Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health Science $31.97/share

    Poništi
  17. prije 17 sati

    Alector Announces FDA Fast Track Designation Granted to AL101 for the Treatment of Patients with Frontotemporal Dementia

    Poništi
  18. prije 17 sati

    CHF Solutions Receives CE Mark for its New Aquadex SmartFlow™ Console

    Poništi
  19. prije 17 sati

    VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE® with a 36-Month Shelf Life

    Poništi
  20. prije 17 sati

    Moleculin to Seek Accelerated FDA Approval and Plans for Pivotal Phase 2 AML Trial

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·